Status:
WITHDRAWN
Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients
Lead Sponsor:
Azidus Brasil
Collaborating Sponsors:
Farmoquimica S.A.
Conditions:
covid19
Eligibility:
All Genders
50+ years
Phase:
PHASE2
PHASE3
Brief Summary
The aim is to demonstrate a decrease in complications among ambulatory patients who are diagnosed with mild COVID-19 by treating them with nitazoxanide for 7 to 14 days on top of standard care compare...
Detailed Description
The aim is to demonstrate a decrease in complications among ambulatory patients who are diagnosed with mild COVID-19 by treating them with nitazoxanide for 7 to 14 days on top of standard care compare...
Eligibility Criteria
Inclusion
- Informed consent from patient or legal representative.
- Subject of both genders (male and female not pregnant and not breastfeeding) aged over 49;
- Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source;
- Symptomatic subject with symptoms for up to 72 hours who does not require hospitalization, with signs and symptoms of acute respiratory viral infection characterized by a feverish sensation or fever, which may or may not be present at the time of the examination (which may be reported to the health professional), accompanied by cough or sore throat or runny nose or difficulty breathing and:
- i) Oxygen saturation ≥ 90%; ii) Risk classification for COVID-19 between low (A) or medium (B) (scores 1 to 19), according to the Brazilian Ministry of Health.
Exclusion
- Participating in another RCT in the past 12 months;
- Presence of comorbidities, which have a contraindication to the use of the study product, not being restricted to:
- HIV or HTLV virus infection;
- Chronic hepatitis C (HCV) treated with direct antiviral drugs;
- Liver failure;
- Severe renal failure, including dialysis;
- Present hypersensitivity to the study product (nitazoxanide), as well as to related compounds;
- Concomitant administration of drugs that may interact with the product under study (nitazoxanide);
- Participants who underwent treatment with other antiviral drugs;
- Subject in antineoplastic treatment with chemotherapy or radiation therapy;
- Subject with severe autoimmune diseases in immunosuppression;
- Transplanted participants;
- Pregnant or lactating women;
- Any other clinical condition that is deemed by the Investigator to be an imminent risk to the health and life of the subject.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04441398
Start Date
July 1 2020
End Date
September 1 2020
Last Update
October 28 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.